Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything

Merck’s $9.2B check to Cidara sits with flu vaccine and pills, highlighting its strategic antiviral investment. Key Points Merck's major acquisition of Cidara Therapeutics demonstrates a clear and proactive strategy to build its next-generation long-term revenue drivers. The acquisition secures a high-potential, late-stage antiviral drug that has already earned key designations from the FDA for its innovative approach. This strategic move reinforces Merck’s strong financial fundamentals and its unwaver ...